title: [Antimicrobial activity of cefodizime against clinical isolates].
abstract: In order to evaluate antimicrobial activity of cefodizime (CDZM), minimum inhibitory concentrations (MICs) of CDZM and control drugs were determined against clinical isolates collected from nation-wide medical institutions and in our laboratory from September to December of 1992 and from September to December of 1995. The results are summarized as follows: 1. Bacterial species with no or few strains resistant to CDZM included Streptococcus pyogenes, Haemophilus influenzae, Citrobacter koseri, Proteus mirabilis and Neisseria gonorrhoeae. The range of MIC values of CDZM against Klebsiella pneumoniae was spread. Other strains, Streptococcus pneumoniae, Moraxella subgenus Branhamella catarrhalis, Escherichia coli, Citrobacter freundii, Enterobacter spp., Serratia marcescens, Proteus vulgaris, Morganella morganii, Providencia spp., Peptostreptococcus spp. and Bacteroides fragilis group were resistant to cephems including CDZM. 2. The MIC90's of CDZM were 0.05 approximately 3.13 micrograms/ml against Streptococcus spp., H. influenzae, M. (B.) catarrhalis, E. coli, Klebsiella spp., P. mirabilis, N. gonorrhoeae and Peptostreptococcus spp. obtained in 1995 that were frequently found in daily treatment of infections. It appears that the effectiveness of CDZM was still relatively high against community-acquired infections. 3. Among H. influenzae isolates included imipenem (IPM)-resistant and norfloxacin (NFLX)-resistant strains. The MIC-range of CDZM against strains collected in 1995 including IPM-resistant and NFLX-resistant strains was < or = 0.025 approximately 0.1 microgram/ml, and MIC90 against these strains was 0.05 microgram/ml. CDZM showed strong antimicrobial activities against H. influenzae strains resistant to carbapenems and new-quinolones.
authors.affiliation: Section of Studies, Tokyo Clinical Research Center.
authors.forename: Y
authors.initials: Y
authors.lastname: Suzuki
authors.forename: R
authors.initials: R
authors.lastname: Ishihara
authors.forename: Y
authors.initials: Y
authors.lastname: Ishii
authors.forename: A
authors.initials: A
authors.lastname: Nakazawa
authors.forename: K
authors.initials: K
authors.lastname: Deguchi
authors.forename: Y
authors.initials: Y
authors.lastname: Matsumoto
authors.forename: C
authors.initials: C
authors.lastname: Nishinari
authors.forename: Y
authors.initials: Y
authors.lastname: Nakane
authors.forename: T
authors.initials: T
authors.lastname: Fukumoto
mesh_terms: D001419:Bacteria / Q000187:drug effects* / Q000302:isolation & purification; D002439:Cefotaxime / Q000031:analogs & derivatives* / Q000494:pharmacology; D002511:Cephalosporins / Q000494:pharmacology*; D004352:Drug Resistance, Microbial; D004926:Escherichia coli / Q000187:drug effects; D006193:Haemophilus influenzae / Q000187:drug effects; D006801:Humans; D007711:Klebsiella pneumoniae / Q000187:drug effects; D009344:Neisseria gonorrhoeae / Q000187:drug effects; D011513:Proteus mirabilis / Q000187:drug effects; D013297:Streptococcus pyogenes / Q000187:drug effects
chemical_list: D002511:Cephalosporins; D002439:Cefotaxime; C033356:cefodizime